Clément Morgat, IMT, obtained a PRISMAP European funded project : https://www.prismap.eu/access/user-projects/
Project summary: Targeted radionuclide therapy has proven to be a valuable therapeutic option for metastatic patients. Novel therapeutic radionuclides emitting short range particles are on the horizon and are expected to provide better efficicacy than 177Lu. However, the current xenografted mice model has severe limitations to truly evaluate the effects of these short range therapeutic emitters due to the absence of isolated metastases. Zebrafish is an emerging model in oncology that allow the implantation of human tumor cells (cell lines or patients’ cells) that can next metastazed to zebrafish organs. Therefore, it is possible to obtain in the same model a primary tumor and isolated metastases. In this project we aimed at using zebrafish embryo as a novel model to better evaluate the efficacy of short range emitters at a multicellular level and on isolated cells. 161Tb and 155Tb will be used as demonstrative examples.
Teams and countries: INCIA, UMR-CNRS 5287, University of Bordeaux; BRIC, University of Bordeaux, France; Institut Laue Langevin/CERN, Grenoble France; IBMM, University of Montpellier, France; Paul Scherrer Institute, Zurich, Switzerland